Climate targets of Rentschler Biopharma successfully approved by SBTi

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announces that the company's near-term climate targets have been officially approved by the Science Based Target initiative.

This approval confirms that our climate targets are set in line with the 1.5°C trajectory set out in the Paris Agreement to keep global warming below catastrophic levels.

We also aim to reduce our Scope 1 and 2 GHG emissions by 37.8% by 2029 from a baseline of 2023, and have committed that 81.8% of our suppliers (by emissions, covering purchased goods and services) will have their own science-based targets by 2029.

The approval of our climate targets by the SBTi is an important milestone in our sustainability journey and we are proud to be part of a group of 7,000 companies worldwide that have set ambitious climate targets to tackle one of the most pressing challenges of our time.

About the SBTi:

The Science Based Targets initiative (SBTi) is a corporate climate action organization that enables companies and financial institutions around the world to do their part to fight the climate crisis. It develops standards, tools, and guidance that enable companies to set greenhouse gas (GHG) emission reduction targets consistent with what is needed to keep global warming below catastrophic levels.